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ABSTRACT 
 
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disease in the 
world, affecting primarily aged populations. The gold standard treatment for PD is still the 
administration of the combination levodopa/aromatic amino acid decarboxylase (AADC) 
inhibitor and, for the past decade, together with the administration of catechol-O-methyl 
transferase (COMT) inhibitors.  
Opicapone is a novel COMT inhibitor, under phase III clinical trials for the treatment of PD. 
When metabolised, opicapone is directly 3-O-sulfated by sulfotransferases (SULT). 
Additionally, both 3-O-methylation and 3-O-glucuronidation compete with 3-O-sulfation for 
conjugation of the adjacent phenolic hydroxyls.  
The purpose of this work was characterizing the kinetics for the conversion of opicapone into 
sulfated metabolite by intestinal, kidney and liver S9 fractions and by human recombinant 
SULTs, using sensitive and specific Liquid Chromatography tandem Mass Spectrometry 
(LC-MS/MS) equipment. The method to quantify the opicapone 3-O-sulfate was developed 
and validated according with FDA regulations for the validation of bioanalytical methods and 
the validation parameters tested were: selectivity/specificity, carryover/contamination, 
dilution integrity, linearity, intra- and inter-batch accuracy and precision. From the tested S9 
fractions, significantly higher levels of opicapone 3-O-sulfate were observed in the human 
intestinal S9 fraction in comparison with the other S9 fractions studied. Human, rat, monkey 
and dog liver S9 fractions, produced small amounts of opicapone 3-O-sulfate and human 
kidney S9 fraction conjugate opicapone at extremely low levels over an incubation period of 
60 min. The apparent kinetic parameters derived from human intestinal and liver S9 fraction 
curve fitted to the allosteric sigmoidal and Michaelis-Menten equations, respectively. Both 
apparent Km and Vmax values were higher for liver than for intestine S9 fraction (12 and 7-fold 
higher, respectively).  
Furthermore, seven commercial available recombinant SULT enzymes (SULT1A1*1, 1A1*2, 
1A2, 1A3, 1B1, 1E1 and 2A1) were also tested in vitro to evaluate opicapone sulfation 
capacity. From the tested SULTs only SULT1A1*1 and 1A1*2 produced significant amounts 
of opicapone 3-O-sulfate (1165.9 ± 127.4 and 1913.2 ± 126.1 fmol.mg prot-1 min-1, 
respectively). SULT1A2, 1A3, 1E1 and 2A1 produced small amounts of opicapone 3-O-
sulfate (between 28.3 – 221.1 fmol.mg prot-1 min-1). No metabolite formation was detected 
with SULT1B1 over an incubation period of 60 min. The opicapone sulfation kinetics was 
performed for the alleles of SULT1A1, SULT1A1*1 and 1A1*2, which fitted with a substrate 
inhibition profile. The apparent affinity for the opicapone conjugation was similar for the two 
alleles, as shown by the apparent Km close to 20 µM.  
The interaction with the SULT substrates, acetaminophen, quercetin and 2,6-dichloro-4-
nitrophenol (DCNP), was also tested. No inhibition was observed on opicapone (100 µM) 
sulfation in the presence of acetaminophen in human liver pooled S9 fraction. Quercetin and 
DCNP completely inhibited opicapone sulfation by human liver S9 fraction with an IC50 of 
1795 nM and 383.3 nM, and with an IC50 of 1483 nM and 181 nM for human intestinal S9 
fraction, respectively. An IC50 of 529 nM and 245 nM was obtained for SULT1A1*1 and an 
IC50 of 232 nM and 700 nM was obtained for SULT1A1*2 for quercetin and DCNP, 
respectively. 
In conclusion, sulfation is a relevant pathway on the metabolic handling of opicapone and 
multiple SULTs are able of catalyzing the sulfation of opicapone. The results obtained in the 
present study also support the role of intestine in opicapone sulfation and strongly suggest 
that in humans, opicapone 3-O-sulfation is mainly catalyzed by SULT1A1 isoforms. 
 
 
 
Keywords: opicapone; opicapone 3-O-sulfate; SULT; sulfotransferases; PAPS; validation; 
LC-MS/MS; S9 fraction; acetaminophen; quercetin; 2,6-dichloro-4-nitrophenol. 
  
RESUMO 
 
A Doença de Parkinson (DP) é a segunda doença neurodegenerativa mais frequente em 
todo o Mundo, afetando principalmente pessoas mais idosas. O principal tratamento 
aplicado atualmente nesta doença continua a ser a administração em combinação de 
levodopa/inibidor da aromatic amino acid descarboxílase (AADC), e mais recentemente, em 
conjunto com um inibidor da catechol-O-methyltransferase (COMT).  
O opicapone é o mais recente inibidor de COMT, atualmente está a ser testado em ensaios 
clínicos de fase III para o tratamento da DP. O metabolito mais abundante do opicapone é o 
3-O-sulfato conjugado pelas sulfotransferases (SULT). A formação deste metabolito 
compete em grande parte com a 3-O-metilação e a 3-O-glucuronização pela conjugação 
dos grupos hidróxilos fenólicos do anel nitrocatecol.  
O objetivo deste trabalho prático foi caraterizar as cinéticas de conversão do opicapone no 
seu metabolito sulfatado através de frações S9 de fígado, rim e intestino, e por 
sulfotransferases recombinantes humanas, recorrendo a um equipamento de Cromatografia 
Liquida acoplada a um Espectrómetro de Massa (LC-MS/MS) altamente sensível e 
específico. O método para a quantificação do sulfato do opicapone foi desenvolvido e 
validado de acordo com as diretivas da FDA para a validação de métodos bio-analíticos e 
os parâmetros de validação testados foram os seguintes: seletividade/especificidade, 
carryover/contaminação, integridade da diluição, linearidade, exatidão e precisão intra- e 
inter-ensaio. Das frações S9 testadas, grandes quantidades de opicapone 3-O-sulfato foram 
observadas em fração S9 de intestino humano em comparação com outras frações S9 
testadas. Frações S9 provenientes de fígado humano, rato, macaco e cão produziram 
pequenas quantidades de opicapone 3-O-sulfato e a fração S9 de rim humano conjuga o 
opicapone a níveis extremamente baixos para um tempo de incubação de 60 min. Os 
parâmetros cinéticos aparentes derivados da fração S9 do intestino e fígado humanos 
correlacionam segundo as equações de Michaelis-Menten e da alostérica sigmoidal, 
respetivamente. Os valores de Km  e Vmax obtidos foram maiores para a fração S9 do fígado 
do que para a fração S9 do intestino (12 e 7 vezes maior, respetivamente). 
Adicionalmente, sete sulfotransferases recombinantes humanas disponíveis 
comercialmente (SULT1A1*1, 1A1*2, 1A2, 1A3, 1B1, 1E1 e 2A1) foram testadas in vitro 
para avaliar a capacidade de sulfatação do opicapone. Das SULTs testadas só as 
SULT1A1*1 e 1A1*2 produziram quantidades significantes de opicapone 3-O-sulfato 
(1165.9 ± 127.4 e 1913.2 ± 126.1 fmol.mg prot-1 min-1, respetivamente). As SULT1A2, 1A3, 
1E1 e 2A1 produziram pequenas quantidades do metabolito sulfatado (entre 28.3 – 221.1 
pmol mg prot-1 min-1). Com a SULT1B1 não se observou a formação de opicapone 3-O-
sulfato durante um período de incubação de 60 min. A cinética da sulfatação do opicapone 
foi realizada para os alelos da SULT1A1, SULT1A1*1 e SULT1A1*2, que corresponderam a 
um perfil de inibição de um substrato. A aparente afinidade para a conjugação do opicapone 
mostrou-se similar para os dois alelos, como demonstrado para o Km aparente perto dos 20 
µM. 
A interação com substratos conhecidos das SULT, como o acetaminofeno, a quercetina e o 
2,6-dicloro-4-nitrofenol (DCNP), também foi testada. Não foi observada nenhuma inibição 
na sulfatação do opicapone (100 µM) na presença do acetaminofeno em fração S9 de 
figado humano. A quercetina e o DCNP inibiram completamente a sulfatação do opicapone 
com um IC50 de 1795 nM e 383.3 nM em fração S9 de fígado humano, e um IC50 de 1483 
nM e 181 nM para a fração S9 de intestino humano, respetivamente. Um IC50 de 529 nM e 
245 nM foi obtido para a SULT1A1*1 e um IC50 de 232 nM e 700 nM foi obtido para a 
SULT1A1*2 para a  quercetina e para o DCNP, respetivamente. 
Em conclusão, a sulfatação é uma via relevante no metabolismo do opicapone e muitas 
SULTs são capazes de conjugar o opicapone. Os resultados obtidos neste trabalho prático 
demonstram adicionalmente o papel do intestino na sulfatação do opicapone e sugerem que 
a 3-O-sulfatação do opicapone em humanos é principalmente catalizada por isoformas 
SULT1A1. 
 
 
 
Palavras-chave: opicapone; opicapone 3-O-sulfato; SULT; sulfotransferases; PAPS; 
validação; LC-MS/MS; fração S9; acetaminofeno; quercetina; 2,6-dicloro-4-nitrofenol. 
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1. PARKINSON DISEASE 
	  
Parkinson’s disease (PD) is a chronic degenerative disease with a prevalence of just over 1 
per 1000 patients and increasing incidence at older ages. It is a movement disorder with 
cardinal features of tremor, rigidity, bradykinesia (slowness of movement), and postural 
instability. Other primary symptoms are slowness, stiffness, and the inability to initiate 
movements. The symptoms of PD become apparent after about 240,000 nigral cells die 
(60% of the total). The peak onset of PD is at 60 years of age and it progresses slowly over 
the next 10 to 20 years. In normal, unaffected people approximately 2400 nigral cells die 
yearly. Thus if someone lives 100 years they are at risk for PD. In PD the nigral cell loss 
accelerates more than 2400 cells die each year. It is unknown why the loss accelerates but 
important clues point at the involvement of some combination of genetic and environmental 
factors. Paralleling the nigral cell loss, there is a loss of the neurotransmitter dopamine in 
another region of the brain: the striatum (Bonifacio et al. 2007). 
The discoveries by Carlsson et al. (1957) (Carlsson et al. 1957) showing that 3,4-
dihydroxyphenylalanine (DOPA) can reverse the inability to initiate movement (akinesia) 
induced by catecholamine depletion in mice. In 1960, Ehringer and Hornykiewicz 
(Hornykiewicz 2006) demonstrating for the first time striatal dopamine deficiency in PD, 
provided the background for the first clinical trials with DOPA. Initial trials led to inconsistent 
results, but some years later Cotzias et al. (Cotzias et al. 1967) reported impressive 
antiparkinsonian effects of long-term oral DL-DOPA, establishing the basis for the modern 
pharmacotherapy of PD. The improved efficacy of the combination of levodopa (L-DOPA) 
with a peripheral decarboxylase inhibitor and the major adverse effects of the treatment, 
including involuntary movements, motor fluctuations, and mental symptoms, were described 
shortly thereafter (Cotzias GC 1969). Levodopa therapy radically changed the life history of 
patients afflicted with PD to such an extent that a large scale, controlled, prospective study 
comparing levodopa versus placebo has never been conducted. 
Levodopa is the most effective symptomatic agent in the treatment of PD and the ‘‘gold 
standard’’ against which new agents must be compared. However, there remain two areas 
of controversy: (1) whether levodopa is toxic, and (2) whether levodopa directly causes 
motor fluctuations and dyskinesias. Levodopa is toxic to cultured dopamine neurons, and 
this may be a problem in PD where there is evidence of oxidative stress in the substantia 
nigra. However, there is little firm evidence to suggest that levodopa is toxic in vivo or in PD. 
Levodopa is also associated with motor complications and increasing evidence suggests 
that they are related, at least in part, to the short half-life of the drug (and its potential to 
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induce pulsatile stimulation of dopamine receptors) rather than to specific properties of the 
molecule. Treatment strategies that provide more continuous stimulation of dopamine 
receptors provide reduced motor complications in PD patients (Olanow et al. 2004). These 
studies raise the possibility that more continuous and physiological delivery of levodopa 
might reduce the risk of motor complications. 
The absorption of levodopa occurs primarily in the duodenum and jejunum by means of an 
amino acid carrier-mediated transport system. Factors that decrease gastric emptying, such 
as food intake, gastric acidity, and anticholinergic medication, can delay the delivery of 
levodopa to the small intestine, allowing more time for peripheral decarboxylation. Protein 
intake may interfere with levodopa treatment because neutral amino acids will compete with 
levodopa for transport across the gut and the blood-brain barrier (BBB) (Pinho et al. 2007a; 
Pinho et al. 2007b). Levodopa is also metabolized in periphery by catechol-O-
methyltransferase (COMT), into 3-O-methyl-levodopa (3-OMD) which may also compete 
with levodopa for transport across these membranes. 
Since its introduction in 1960s, levodopa has been the mainstay of treatment for PD. Unlike 
dopamine, levodopa crosses the BBB and it is then decarboxylated to dopamine by aromatic 
amino acid decarboxylase (AADC) and is released by presynaptic terminals in the striatum, 
where it replenishes the dopaminergic deficiency that is characteristic of PD (Figure 1). 
Given orally, levodopa is approximately 95% decarboxylated by the intestinal and liver 
AADC to dopamine, which, as mentioned above, cannot cross the BBB and by these 
conditions the amount of levodopa that reaches the brain is, nevertheless, very low, about 
1% of the administered dose. The combination of levodopa with a decarboxylase inhibitor 
(carbidopa or benserazide), which is unable to penetrate the Central Nervous System 
(CNS), diminishes the decarboxylation of levodopa to dopamine in peripheral tissues and 
enable a greater proportion of levodopa to reach the target sites in the striatum. As a result 
the levodopa dose can be reduced until 70%-80% maintaining the clinical efficacy. 
Therefore, although the same dosage is used, the peripheral side effects of levodopa and 
dopamine (nausea, hypotension, etc.) were minimizes, since circulating dopamine returns to 
physiological levels (Bonifati et al. 1999; Deleu et al. 2002). 
COMT is an enzyme that efficiently metabolize levodopa this being particularly evident when 
given with decarboxylase inhibitors. COMT (EC 2.1.1.6), initially described by Axelrod and 
Tomchick in 1958, catalyzes the transference of a methyl group from S-adenosyl-L-
methionine (SAM) to a hydroxyl group of a catechol substrate in the presence of 
magnesium, the reaction products being the O-methylated catechol and S-adenosyl-L-
homocysteine (Guldberg et al. 1975). 
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COMT inhibition prevents the normal O-methylation of levodopa to its metabolite 3-OMD, a 
reaction that diverts a portion of the levodopa from conversion to dopamine. By limiting this 
‘‘metabolic loss’’ of levodopa to 3-OMD, COMT inhibitors increase the availability of 
levodopa for dopamine production. COMT inhibitors, taken orally in combination with 
levodopa and carbidopa or benserazide, reduce peripheral 3-OMD formation from levodopa, 
enabling more levodopa to enter the brain. Carbidopa and benserazide are also substrates 
for COMT, and COMT inhibitors may prolong the action of these decarboxylase inhibitors. 
 
 
Figure 1 - Dopamine synthesis and metabolism: AADC, aromatic amino acid decarboxylase; COMT, catechol-O-
methyltransferase; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanilic acid; MAO, monoamine oxidase; TH, tyrosine 
hydroxylase; 3-MT, 3-methoxytyramine; 3-OMD, 3-O-methyldopa. 
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2. COMT INHIBITORS 
	  
COMT substrates comprise a wide variety of endogenous and exogenous catechol 
derivatives such as catecholamines, their hydroxylated metabolites, catecholestrogens, 
ascorbic acid, dietary phytochemicals, and therapeutic compounds (Guldberg et al. 1975; 
Mannisto et al. 1992; Zhu et al. 2000). The major physiological role of the O-methylation 
reaction is the inactivation of biologically active or toxic catechols. Of particular relevance is 
the methylation of levodopa to 3-OMD in patients with PD (Sharpless et al. 1971; Mannisto 
et al. 1990). Recent studies also suggest a relevant role of COMT in modulating prefrontal 
dopamine neurotransmission (Egan et al. 2002; Huotari et al. 2002; Akil et al. 2003; Bilder et 
al. 2004). Two molecular forms of the enzyme have been described in mammals, a soluble 
form (S-COMT) and another form associated with membranes (MB-COMT) (Borchardt 1974; 
Jeffery et al. 1984; Grossman et al. 1985) both encoded by a single COMT gene (Salminen 
et al. 1990; Lundström et al. 1991; Winqvist et al. 1992). 
MB-COMT and S-COMT have in common similar affinities for SAM (Jeffery et al. 1987; Lotta 
et al. 1995), the requirement for magnesium, the inhibition by calcium, and the similar 
optimal pH for activity (Mannisto et al. 1999). The affinity for substrates can, however, be 
significantly different. MB-COMT has typically higher affinity for catecholamines (10- to 100-
fold higher) than S-COMT, and this characteristic appears to be horizontal to different 
species. The reason for this difference is not yet clarified; however, it is probably due to 
interactions between the protein and the membrane through lipids and other membrane 
proteins (Lotta et al. 1992; Bonifácio et al. 2000). 
Following to the first purification and characterization of COMT, in the late 1950s (Axelrod et 
al. 1958), several classes of COMT inhibitors were identified. A comprehensive review of the 
pharmacological properties of these first-generation COMT inhibitors was published by 
Guldberg and Marsden (1975). Those compounds are typically competitive substrates of 
COMT and contain a catechol structure, or some related bioisosteric moiety. They include 
derivatives of pyrogallol and catechols, such as gallic acid, caffeic acid, 2-
hydroxyoestrogens, or flavonoids like quercetin or rutin. Moreover, several other 
noncatecholic compounds like ascorbic acid, tropolones and derivatives of 8-
hydroxyquinolines, and 3-hydroxylated pyrones and pyridones were identified as COMT 
inhibitors. 
The potencies of these compounds were only moderate, with large dissociation constants 
typically within the micromolar range, but on the other hand, they proved to be useful for the 
study of adrenergic mechanisms. Some of these COMT inhibitors showed little value as 
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pharmacological agents, due to unfavorable pharmacokinetics, poor selectivity, or toxicology 
(Ericsson 1971; Guldberg et al. 1975; Reches et al. 1984).  
The interest in COMT, especially as a therapeutic target, was strongly revived with the 
discovery of second-generation COMT inhibitors, in the late 1980s. Two independent groups 
developed simultaneously a new class of disubstituted catechols as a new generation of 
potent and selective COMT inhibitors (Bäckström et al. 1989; Borgulya et al. 1989; Männistö 
et al. 1989). Structure–activity relationship analysis established that enhanced potency was 
obtained by substitution with electron-withdrawing groups at a position ortho to a hydroxyl 
group of the catechol moiety. The best results were obtained with the nitro group, hence 
giving rise to a new class of nitrocatecholic COMT inhibitors. The concentration of the most 
potent nitrocatechols necessary to inhibit 50% of COMT activity in vitro was typically in the 
low nanomolar range, which indicates a potency three orders of magnitude higher than that 
of typical first-generation COMT inhibitors. 
Nitrocatechols are kinetically characterized as reversible tight-binding inhibitors of COMT 
(Schultz et al. 1989; Lotta et al. 1995; Borges et al. 1997). Although poor substrates for the 
enzyme, they behave competitively with respect to the catechol substrate and are 
uncompetitive with respect to the co-substrate SAM (Schultz et al. 1989). Moreover, the new 
inhibitors showed increased selectivity for COMT over other enzymes involved in the 
metabolism of catecholamines, such as tyrosine hydroxylase, dopamine-β-hydroxylase, 
AADC, or monoamine oxidase (A and B forms) (Bäckström et al. 1989).  
Of the initial series of nitrocatechol COMT inhibitors, nitecapone, entacapone, and tolcapone 
were characterized in detail. A direct comparison of the three inhibitors indicated values of Ki 
of 1.02, 0.30, and 0.27 nM for nitecapone, entacapone, and tolcapone, respectively (Lotta et 
al. 1995).  
Ex vivo, tight-binding inhibitors are orally active and reversibly inhibit COMT activity, to a 
significant level, in a variety of tissues in the rat. While nitecapone has its main site of action 
in the duodenum (Nissinen et al. 1988), the structurally related entacapone shows significant 
COMT inhibition in other peripheral tissues, such as the liver and erythrocytes. However, it is 
essentially a peripheral COMT inhibitor, with only limited and transient inhibition of brain 
COMT at the higher doses tested (Nissinen et al. 1988; Learmonth et al. 2002). Tolcapone, 
on the other hand, by oral administration to rats has a higher potency and a longer duration 
of action than entacapone (Zurcher et al. 1990; Learmonth et al. 2002). Moreover, tolcapone 
can easily cross the BBB, showing almost indiscriminate inhibition of both peripheral and 
brain COMT (Zurcher et al. 1990; Zurcher et al. 1990; Borgulya et al. 1991; Learmonth et al. 
2002).  
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More recently, several structure–activity relationship studies undertaken by another research 
group led to the development of two new nitrocatecholic COMT inhibitors, with superior 
pharmacological characteristics. Nebicapone (Learmonth et al. 2002) and BIA 3-335 
(Learmonth et al. 2004) incorporate the nitrocatechol pharmacophore and show the typical 
tight-binding characteristics of other nitrocatechols, being potent and reversible competitive 
inhibitors of COMT (Bonifacio et al. 2003). 
It has been demonstrated that these COMT inhibitors together with an AADC inhibitor such 
as carbidopa or benserazide, alter the metabolism of levodopa and effectively potentiate the 
action of orally administered levodopa. Indeed, the levels of 3-OMD are markedly reduced 
and the bioavailability of levodopa in the plasma is increased, when levodopa plus AADC 
inhibitor are orally administered to rats, together with nitecapone (Nissinen et al. 1988), 
entacapone (Nissinen et al. 1992), tolcapone (Borgulya et al. 1989; Zurcher et al. 1990; 
Zurcher et al. 1990) and nebicapone (Loureiro et al. 2006). 
Tolcapone, entacapone, and nebicapone are extensively metabolized, mostly in liver. The 
major metabolic pathways of these compounds involve conjugative reactions. The 3 O-β,D-
glucuronide conjugates of tolcapone and nebicapone are the major plasma metabolites. 
Tolcapone and nebicapone are also methylated (Jorga et al. 1999; Loureiro et al. 2006) and 
the respective metabolites, although present in minor concentrations in human plasma, have 
very long half-lives, which may suggest that accumulation could occur. However, during 
long-term administration only a relatively small accumulation of the methylated metabolite 
occurs, due to the suppression of its formation by the COMT inhibitor itself. Entacapone is 
not methylated in humans. Minor metabolic pathways in humans include oxidative or 
reductive reactions and further conjugation of the derived products for tolcapone (Jorga et al. 
1999), and sulfate conjugation and nitro reduction followed by acetylation for nebicapone 
(Loureiro et al. 2006). 
Entacapone and tolcapone are the COMT inhibitors currently available in the market. 
Nevertheless, whilst they have improved the treatment of PD, both compounds exhibit 
important drawbacks that limit their clinical success; entacapone exhibits a limited clinical 
efficacy, while tolcapone must be used under strict hepatic monitoring due to its severe liver 
toxicity (Deleu et al. 2002; Keating et al. 2005; Bonifacio et al. 2007; Lees 2008).	  
Opicapone (2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophenyl]-1,2,4-oxadiazol-3-yl)-4,6-dimethyl 
pyridine 1-oxide, also known as BIA 9-1067) (Figure 2) is a novel third generation COMT 
inhibitor currently under phase III clinical trials by BIAL – Portela & Cª, S.A. (S. Mamede do 
Coronado, Portugal) for use as adjunctive therapy in levodopa-treated PD patients. 
Opicapone was designed as a hydrophilic 1,2,4-oxadiazole analogue with a pyridine N-oxide 
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residue at position 3 to provide high COMT inhibitory potency and avoid cell toxicity (Kiss et 
al. 2010). 
Actually, it is crucial the need for development of more potent, safer and longer acting 
COMT inhibitors, at this point, opicapone is emerging as a candidate for this unmet need. 
Opicapone is endowed with an exceptionally high binding affinity (sub-picomolar Kd) that 
translates into a slow complex dissociation rate constant and a long duration of action in vivo 
(Bonifácio et al. 2012a; Bonifácio et al. 2012b). In liver and brain homogenates from rats 
administered with opicapone, tolcapone and entacapone by gastric tube, opicapone showed 
to have a stronger and more sustained COMT inhibitory effect than the comparing COMT 
inhibitors tolcapone and entacapone. One hour after administration, COMT inhibition was 
99% with opicapone versus 82% with tolcapone and 68% with entacapone. Nine hours after 
administration, entacapone showed no COMT inhibition and tolcapone produced minimal 
inhibitory effect (16%), whereas opicapone continued to inhibit COMT activity by 91% 
(Bonifácio et al. 2012b). Opicapone was well tolerated in studies in several animal species. 
On basis of these promising results, it was decided to proceed to further clinical trials with 
opicapone. In PD patients, opicapone as adjunctive therapy to a combination of 
levodopa/AADC inhibitor showed to increase levodopa systemic exposure, decrease 3-OMD 
exposure, decrease S-COMT activity and improves patients’ motor performance in clinical 
studies (Kiss et al. 2010; Rocha et al. 2013).  
 
 
 
 
	  
Figure 2 - Chemical struture of opicapone (formerly known as BIA 9-1067). 
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3. OPICAPONE METABOLISM 
	  
The biotransformation of substances foreign to the body (xenobiotics) including drugs is 
divided into phase I and phase II. Phase I reactions are performed by the main enzymes 
cytochromes P450 (CYPs) and include the transformation of a parent compound to more 
polar metabolites, mainly hydroxylations and hence acting as monooxygenases, 
dioxygenases and hydrolases. The cytochromes P450 constitute a superfamily of heme 
enzymes responsible for the metabolism of xenobiotics and endobiotics. They are also 
involved in a variety of specific endogenous functions including the biosynthesis of steroid 
hormones, prostaglandins, bile acids, and others (Anzenbacher et al. 2001; Nebert et al. 
2002). Only about a dozen enzymes belonging to the 1, 2, and 3 CYP-families are 
responsible for the metabolism of the majority of drugs and other xenobiotics. Despite the 
broad and overlapping substrate specificities of these enzymes, many drugs are 
metabolized at clinically relevant concentrations by one or few enzymes only, which limits 
the important redundancy of the phase I drug oxidation system. Knowledge of the intrinsic 
and extrinsic factors that influence expression and function of the responsible enzymes is 
thus a prerequisite for predicting variable pharmacokinetics and drug response. While 
monogenic polymorphisms explain a major part of the variability for only few enzymes (in 
particular CYP2D6), most enzymes are multifactorially controlled including additional 
polymorphisms in regulatory trans-genes and nongenetic host factors including sex, age, 
disease, hormonal and diurnal influences and other factors. Summarizing, the highest 
expressed forms in liver are CYPs 3A4, 2C9, 2C8, 2E1, and 1A2, while 2A6, 2D6, 2B6, 
2C19 and 3A5 are less abundant and CYPs 2J2, 1A1, and 1B1 are mainly expressed 
extrahepatically. 
Phase II enzymes play also an important role in the biotransformation of endogenous and 
xenobiotics compounds to more easily excretable forms as well as in the metabolic 
inactivation of pharmacologically active substances. The phase II reactions are currently 
designed by conjugating reactions. These include glucuronidation, sulfation, methylation, 
acetylation, glutathione and amino acid conjugation. In general, the respective conjugates 
are more hydrophilic than the parent compounds. 
Phase II drug metabolizing enzymes are mostly transferases and include: UDP-
glucuronosyltransferases (UGT), sulfotransferases (SULT), N-acetyltransferases (NAT), 
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glutathione S-transferases (GST) and various methyltransferases (mainly thiopurine S-
methyltransferase, TPMT and catechol-O-methyl transferase, COMT) (Jancova et al. 2010). 
When metabolised, these nitrocatechol derivatives are extensively conjugated, usually 
undergo direct glucuronidation catalysed by UGTs, sulfation catalysed by SULTs and are 
then rapidly excreted in the urine (Lautala et al. 1997; Loureiro et al. 2006). Additionally, 
methylation may compete with other metabolic pathways for conjugation of the adjacent 
phenolic hydroxyls (Jorga et al. 1999; Loureiro et al. 2006). Minor metabolic pathways of 
COMT inhibitors in humans include oxidative or reductive reactions due to the presence of 
adjacent phenolic hydroxyls on nitrocatechol that is more favourable in metabolism involving 
conjugation reactions. 
As have been shown for other COMT inhibitors, opicapone is metabolized into opicapone 3-
O-sulfate, which is the major inactive metabolite in plasma, suggesting that the sulfation is 
the main metabolic pathway for opicapone (Figure 3). Additionally, both 3-O-methylation and 
3-O-glucuronidation were observed as minor metabolites that compete with 3-O-sulfation for 
conjugation of the adjacent phenolic hydroxyls. The opicapone amine N-oxide reduced form, 
showed also to be a minor metabolite (Rocha et al. 2013). 
 
 
 
Figure 3 – Metabolic pathways for opicapone. Chemical structures of opicapone and its metabolites.. SULT, sulfotransferase; 
PAPS, 3’-phosphoadenosine 5’-phosphosulfate; PAP, 3’-phosphoadenosine 5’-phosphate.	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3.1. SULFOTRANSFERASES 
	  
Sulfotransferases are a supergene family of enzymes that catalyse the conjugation of 3’- 
phosphoadenosine 5’- phosphosulphate (PAPS) with an O-, N- or S- acceptor group of an 
appropriate molecule. In general, O-sulfation represents the dominant cellular sulfation 
reaction. Nevertheless, N-sulfation is a crucial reaction in the modification of carbohydrate 
chains in macromolecules such as heparin and heparan sulfate, common components of 
proteoglycan. N-Sulfoconjugation is also involved in the metabolism of xenobiotics such as 
quinolones and amino drugs (Senggunprai et al. 2009). The PAPS is a universal sulfate (or, 
correctly sulfonate) donor molecule required for all sulfonation reactions and shown that it 
can be synthesized by all tissues in mammals (Strott 2002). All the human cells are capable 
to synthesize PAPS in cytoplasm by a two-step reaction utilizing ATP and inorganic sulfate 
(Figure 4). The inorganic sulfate used in the synthesis of PAPS may come from the diet, 
renal reabsorption or from the catabolism of the amino acids cysteine and methionine 
(Klaassen et al. 1997). The sulfation of drugs in humans may be limited by the availability of 
PAPS, because the synthesis of PAPS depends on the availability of inorganic sulfate in 
plasma. High doses of substrates for glutathione conjugation, sulfation, and amino acid 
synthesis as well as by genetic defects in PAPS synthesis may deplete the levels of 
inorganic sulfate in plasma. A sulfation decrease due to the depletion of PAPS may increase 
the toxicity of some drugs such as acetaminophen (Falany 1997; Klaassen et al. 1997). 
Sulfation has a significant role in the biotransformation of a number of endogenous low-
molecular compounds (e.g. steroids, catecholamines, serotonin, iodothyronines, 
eicosanoids, some tyrosine-containing peptides, retinol, 6-hydroxymelatonin, ascorbate and 
vitamin D) (Glatt et al. 2004). Furthermore, it is an important pathway in the 
biotransformation of numerous xenobiotics such as drugs and chemicals (Gamage et al. 
2006). On the other hand, a number of compounds (procarcinogens) are converted by 
sulfation into highly reactive intermediates which can act as chemical carcinogens and 
mutagens by covalently binding to DNA (Surh 1998; Glatt et al. 2004; Jancova et al. 2010).  
Human SULTs are divided into four families: SULT1 (phenol SULTs), SULT2 
(hydroxylsteroid SULTs), SULT4 and SULT6. Sulfation of phenolic xenobiotics is performed 
by SULT1 family, and sometimes by SULT2 (Allali-Hassani et al. 2007). The SULT1 family 
involves 8 members divided into 4 subfamilies (1A1, 1A2, 1A3, 1B1; 1C1, 1C2 and 1C3; 
1E1). The SULT2 family can be divided into two subfamilies, SULT2A (SULT2A1 and 
SULT2A3) and SULT2B that comprises two isoforms SULT2B1a and SULT2B1b. The 
SULT4A1 and SULT6B1 are the only members of the SULT4 and SULT6 family 
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respectively. The members of the same SULT gene family share at least 45 % amino acid 
sequence identity while members of subfamilies share at least >60 % identity in amino acid 
sequence. Two broad classes of sulfotransferases have been identified: namely the 
cytosolic and membrane-bound ones. Membrane-bound SULTs are localized in the Golgi 
apparatus and are responsible for the sulfation of peptides, proteins, lipids and 
glycosaminoglycans. Cytosolic SULTs catalyze sulfation of xenobiotics and small endobiotic 
molecules such as steroids, bile acids and neurotransmitters. SULTs exhibit wide tissue 
distribution. The members of SULT1A subfamily have been identified in liver, brain, breast, 
intestine, jejunum, lung, adrenal gland, endometrium, placenta, kidney and blood platelets 
and is subject to a common genetic polymorphism (Price et al. 1989). Common single 
nucleotide polymorphisms have been reported in the human SULT1A1 gene (Jones et al. 
1995; Raftogianis et al. 1996). The common SULT1A1 allozymes include *1 which as an Arg 
in position 213, the *2 variant defined by an Arg213His amino acid substitution due to a 
conversion from Guanine (G) to Adenine (A) at nucleotide 638. These single nucleotide 
polymorphisms lead to changes in thermal stability, enzymatic activity, and altered 
degradation of the allozymes (Raftogianis et al. 1997; Raftogianis et al. 1999; Nagar et al. 
2006). SULT1A1 exhibits the highest level of expression of all SULT1 enzymes in the liver. 
In contrast, SULT1A3 is expressed in most tissues with the exception of adult liver and 
SULT1B1 in liver, small intestine, colon and leukocytes. Expression of the SULT1C 
subfamily is found predominantly in the human fetus, SULT1E1 is expressed in the human 
liver and jejunum. SULT2A1 shows the highest level of expression in liver, adrenal, 
duodenum and fetal adrenal gland. Subfamily SULT2B is localized in human prostate, 
placenta, adrenal gland, ovary, lung, kidney and colon (Glatt et al. 2004; Gamage et al. 
2006; Lindsay et al. 2008). Human SULT4A1 has been identified in brain and SULT6B1 in 
testis and kidney (Jancova et al. 2010). 
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Figure 4 – The two-step synthesis of PAPS. ATP, adenosine triphosphate; APS, adenosine 5’-
phosphosulfate; PPi, inorganic pyrophosphate; ADP, adenosine diphosphate. 
 
	  
SULT enzymes have different substrate preferences although there is evidence of substrate 
overlap at the levels of subfamilies and families.  
SULT1A1 is a xenobiotic-conjugating enzyme with a broad substrate range with specificity 
for small phenolic compounds. It has also been termed phenol sulfotransferase (P-PST) and 
thermostable phenol sulfotransferase (TS PST1). This form is responsible for the 
sulfoconjugation of phenolic compounds such as monocyclic phenols, naphtols, benzylic 
alcohols, aromatic amines, hydroxylamines, dopamine and iodothyronines (Glatt et al. 
2004). The SULT1A1 has high affinity for 4-nitrophenol, sensitivity to inhibition by 2,6-
dichloro-4-nitrophenol (DCNP) and quercetin and its thermostability at 45 ºC (Dajani et al. 
1998; De Santi et al. 2002; Hempel et al. 2007). 
SULT1A2 (TS PST2) appears to be an efficient enzyme in sulfating some aromatic 
hydroxylamines (Meinl et al. 2002; Nowell et al. 2005), and this reaction forms charged 
species (the sulfoconjugates of hydroxylamines) which may suggest a potential role in 
mutagenicity and carcinogenicity. This is an example of a toxification reaction, contrary to 
detoxication reactions occurring in the majority of cases. The physiological role of SULT1A2 
has not been identified yet (Nowell et al. 2005). SULT1A2 can sulfoconjugate substrates 
such as 2-naphtol or 4-nitrophenol (Glatt et al. 2004). Although, SULT1A2 shares >93 % 
amino acid identity with SULT1A1 and SULT1A3, this enzyme exhibits no activity toward 
dopamine as a substrate (Gamage et al. 2006). 
SULT1A3 was previously known as thermolabile phenol SULT (TL PST) and monoamine 
phenol sulfotransferase (M-PST). It displays high affinity for monocyclic phenols. SULT1A3 
has a strong substrate preference for endogenous catecholamines and as such is 
responsible for the regulation of the rapidly fluctuating levels of neurotransmitters. Dopamine 
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is often used as a selective substrate for the detection of SULT1A3 activity (Dajani et al. 
1998). Norepinephrine, catechols, monocyclic phenols and aromatic molecules are other 
substrates of SULT1A3 (Gamage et al. 2006). 
The substrate specifity of SULT1B1 is restricted to thyroid hormones (Fujita et al. 1997) and 
small phenolic compounds such as 1-naphtol and 4-nitrophenol (Pai et al. 2002). 
SULT1C1 conjugates some iodothyronines, 4-nitrophenol and N-hydroxy-2-
acetylaminofluorene (Li et al. 2000) but a good endogenous substrate for this enzyme has 
not been identified. 
SULT1C2 showed activity for substrates as 4-nitrophenol and N-hydroxy-2-
acetylaminofluorene (Yoshinari et al. 1998). 
SULT1E1 is widely known as estrogen sulfotransferase (EST). This enzyme has a greater 
affinity for estrogen sulfation than any other SULTs that conjugate estrogen (Falany et al. 
1995; Schrag et al. 2004). SULT1E1 may be important in both the metabolism of estrogens 
and in the regulation of their activities. This enzyme also shows activity towards 
iodothyronines, pregnenolon, 1-naphtol, naringenin, genistein and 4-hydroxytamoxifen 
(Gamage et al. 2006). 
SULT2A1 was termed dehydroepiandrosterone-sulfotransferase (DHEA ST). This form is 
known to sulfonate steroids, drugs, and other xenobiotics and is highly selective for DHEA 
(dehydroepiandrosterone) (Comer et al. 1993; Cook et al. 2012). 
SULT2A and SULT2B subfamilies conjugate similar substrates but members of the SULT2B 
subfamily are predominantly cholesterol sulfotransferases (Javitt et al. 2001). 
To date no substrates have been identified for SULT4A1 or SULT6B1 (Lindsay et al. 2008; 
Minchin et al. 2008). 
SULT activity may be inhibited in humans exposed to certain therapeutic drugs, dietary or 
environmental chemicals (Wang et al. 2006). The inhibitory effects of various compounds 
have been examined mainly for the SULT1A subfamily. Vietri et al. (Vietri et al. 2003) 
described curcumin as a potent inhibitor of SULT1A1 in human liver. De Santi et al. (De 
Santi et al. 2002) showed inhibition of SULT1A1 by quercetin in human adult and fetal liver. 
The inhibitory effects of various beverages and catechins in tea were investigated by 
Nishimuta et al. (Nishimuta et al. 2007). Their results showed inhibition of recombinant 
SULT1A1 and 1A3 by grapefruit juice, orange juice, green tea, black tea and oolong tea. An 
inhibitory effect of some non-steroidal anti-inflammatory agents on SULT1A1 and SULT1E1 
activity was demonstrated by King et al. (King et al. 2006). Nimesulide, meclofenamate, 
piroxicam were selective inhibitors of SULT1A1 while sulindac and ibuprofen were more 
selective for SULT1E1 inhibition.  
FCUP/BIAL 
Opicapone Sulfation: Sulfotransferase Isoforms Characterization	  
31 
	  
Maiti et al. (Maiti et al. 2005) found that retinoic acid can increase sulfotransferase 
expression and activity in cultured human cells. They reported retinoic acid induction of 
human SULT1A1, 2A1 and 1E1 in hepatic carcinoma cells (HepG2) and in intestinal 
carcinoma cells (Caco-2). Methotrexate induced human SULTs in HepG2 and Caco-2 cells 
(Chen et al. 2005). Chen el al. showed that protein and mRNA expression of human 
SULT1A1, 1A3, 2A1, 1E1 were induced in HepG2 cells; SULT1A3 and 2A1 were induced in 
Caco-2 cells. Sulfotransferase expression in HepG2 and Caco-2 cell lines was also 
investigated by Chen et al. (Chen et al. 2008). Their data suggested that genistein, a natural 
isoflavone found in soybean products induced SULT1A1 and SULT2A1 gene and protein 
expression in these cells (Jancova et al. 2010). 
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4. OBJECTIVES 
 
4.1. GENERAL OBJECTIVE 
	  
Since identification of SULTs isoforms helps to predict potential drug-drug interaction 
mediated by particular enzyme isoform and polymorphism-related interindividual variability, 
we thought it should be useful to identify the SULTs involved in opicapone sulfation, using 
human liver and intestinal S9 fraction and recombinant SULTs. 
The overall purpose of this study was to identify the SULTs involved in opicapone sulfation 
and to characterize their kinetics parameters using human intestinal and liver S9 fractions 
and human recombinant sulfotransferases. 
 
4.2. SPECIFIC OBJECTIVES 
	  
• To develop and validate a LC-MS/MS method for the quantification of opicapone 3-
O-sulfate; 
 
• To characterize the kinetics parameters of opicapone conjugation into opicapone 3-
O-sulfate by S9 fractions from different species; 
 
• To characterize the kinetics parameters of opicapone conjugation into opicapone 3-
O-sulfate by human recombinant sulfotransferases; 
 
• To characterize the interaction between SULT substrates, acetaminophen, quercetin 
and DCNP in opicapone sulfoconjugation.  
	   	  
  
 
 
 
 
 
 
 
 
 
CHAPTER II 
 
MATERIAL AND METHODS 
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1. REAGENTS 
	  
Opicapone (code name BIA 9-1067); 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-
oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide; opicapone 3-O-sulfate (code name BIA 9-
1103); pyridinium 5-(3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-3-yl)-1,2,4-oxadiazol-5-yl)-2-
hydroxy-3 nitrophenyl sulfate; were synthesized in the Laboratory of Chemistry, BIAL (S. 
Mamede Coronado, Portugal), with purities >99.5%.  
Acetaminophen, quercetin and 2,6-dichloro-4-nitrophenol were purchased from Sigma-
Aldrich (St. Louis, MO). The 3’-phosphoadenosine 5’-phosphosulfate (PAPS), magnesium 
chloride (MgCl2), potassium phosphate monobasic (KH2PO4) and potassium phosphate 
dibasic (K2HPO4) were purchased from Sigma-Aldrich (St. Louis, MO). All the compounds 
mentioned above were stored in accordance to the certificates of analysis retained in Bial’s 
Laboratory of Pharmacological Research.  
Pooled liver S9 from human, monkey, rat and dog were purchased from BD Gentest 
(Woburn, MA). Pooled human intestinal S9 fraction and kidney S9 fraction were purchased 
from XenoTech (Lenexa, KS). Recombinant human SULT expressed in Escherichia coli 
were purchased from Cypex (Scotland, UK, SULT: 1A1*1, 1A1*2, 1A2, 1A3, 1B1, 1E1 and 
2A1). The protein contents were used as described in the data sheets provided by the 
manufacturers. 
 
All the biological material was appropriately handled with gloves and all disposable materials 
were incinerated. 
 
  
FCUP/BIAL 
Opicapone Sulfation: Sulfotransferase Isoforms Characterization	  
35 
	  
2. LABORATORY EQUIPMENT 
	  
The laboratory equipment used is present next: 
 
- Automatic Pipettes Gilson PIPETMAN®; 
- Multipette Plus Eppendorf®; 
- Balance Kern® ABJ; 
- Balance Mettler Toledo® XP26; 
- Digital Timer Smiths; 
- Magnetic Stirrer IKA®; 
- MilliQ Water System (Millipore®); 
- Shaking Water Bath GFL®; 
- Digital Thermometer Checktemp 4 (HANNA® Instruments); 
- Fume Hood mc6® Waldner; 
- Centrifuge Eppendorf® 5417R; 
- Vortex Mixer SA8 Stuart®; 
- Agilent® LC TQ/MS (Agilent Technologies, CA, United States). 
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3. SOFTWARES 
	  
The softwares used for data collection and data analysis are the ones described next: 
 
- GraphPad Prism® 5.02 (GraphPad Software, Inc.); 
- Microsoft Office® Excel 2007; 
- Agilent MassHunter® Workstation Software Version B.04.01. 
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4. OPICAPONE SULFATION  
	  
4.1. OPICAPONE SULFATION BY S9 FRACTIONS 
	  
The sulfation of opicapone by human, monkey, rat and dog S9 fractions were performed in 
the incubation mixture contained the following: 50 mM phosphate buffer (pH 7.4); 5 mM 
MgCl2; 0.1 mM PAPS and S9 (0.4 mg/ml and 1.0 mg/ml) suspension in 50 mM phosphate 
buffer (pH 7.4). The mixture was pre-incubated for 5 min at 37ºC, and then the compound 
(10 µM) was added to initiate the assay. The samples were incubated at 37 ºC for 30 to 120 
min. After incubation the reaction was stopped with acetonitrile 0.1% formic acid and 
samples, centrifuged (approx. 14000 g for 10 min), filtered (6000 g for 5 min) and injected 
into LC-MS/MS. The incubation without PAPS was performed for 60 min. 
 
4.2. OPICAPONE SULFATION BY RECOMBINANT SULFOTRANSFERASES 
	  
Opicapone sulfation by SULT1A1*1, 1A1*2, 1A2, 1A3, 1B1, 1E1 and 2A1 was measured 
using the following assay conditions: the incubation mixture (100 µl total volume) contained 
0.4 mg/ml total protein, 5 mM MgCl2, 0.1 mM PAPS, in 50 mM phosphate buffer (pH 7.4) 
and 10 µM opicapone. Drug was dissolved in DMSO and the final concentration of DMSO in 
the reaction was below 0.5% (v/v). The mixture was pre-incubated for 5 min at 37ºC, and 
then the compound was added to initiate the assay. The samples were incubated for up to 
60 min and stopped with 100 µl acetonitrile 0.1% formic acid. All incubations were performed 
in a shaking water bath at 37ºC. After removal of the protein by centrifugation for 10 min at 
14000g, supernatant was filtered (6000 g for 5 min) and injected into LC-MS/MS.  
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4.3. KINETIC OF OPICAPONE SULFATION BY HUMAN RECOMBINANT 
SULFOTRANSFERASES AND POOLED HUMAN LIVER AND INTESTINAL S9 
FRACTION 
 
Rates of sulfation were determined, as described above for SULT screening, with opicapone 
concentrations ranging 5-100 µM and with 60 min incubation time for all recombinant 
SULTs, SULT1A1*1, 1A1*2, 1A2, 1A3, 1B1, 1E1 and 2A1, and for human liver and intestinal 
S9 fractions. All preparations were evaluated for linearity of product formation with respect to 
incubation time (0-240 min) and protein concentration. The total protein concentration was 
30 µg/ml for SULTs, 0.4 mg/ml for HIS9 and 1.0 mg/ml for HLS9. All experiments were 
performed with samples in duplicate. 
 
 
4.4. INHIBITION OF OPICAPONE SULFATION BY TYPICAL SUBSTRATES FOR 
SULT ISOFORMS 
	  
In experiments designed to evaluate the inhibition of opicapone sulfation, human pooled S9 
fractions and SULT1A1*1 and 1A1*2 were incubated for 60 min with 100 µM opicapone in 
the presence and in the absence of the following substrates: acetaminophen, (substrate for 
SULT) at the concentrations of 1, 5, 10, 50, 100, 200, 400 and 500 µM; quercetin (substrate 
for SULT1A1) and 2,6-dichloro 4-nitrophenol (substrate for SULT1A1) at 0.05, 0.1, 0.5, 1, 5, 
10, 50, 100 µM. The opicapone sulfation was determined as described above for SULT 
screening. 
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5. BIO-ANALYTICAL METHOD VALIDATION 
	  
Bio-analytical method validation included all the procedures that demonstrate that the 
method used for a quantitative measurement of opicapone 3-O-sulfate in a given matrix, is 
reliable and reproducible for the intended use.  
Validation involved documenting, through the use of specific laboratory investigations, that 
the performance characteristics of the method were suitable and reliable for analytical 
applications. 
The validation criteria were established in such a way to define the necessary parameters 
for validation of the analytical method (Blume et al. 2010; DeSilva et al. 2012). 
 
 
5.1. REFERENCE STOCK SOLUTIONS 
	  
Two separate stock solutions (one for calibration standards and other for quality controls 
specimens) of opicapone 3-O-sulfate were prepared by accurately weighing an appropriate 
amount of compound and dissolving it in DMSO to obtain 10 mM solutions. Opicapone 3-O-
sulfate stock solutions were prepared freshly every day. 
 
 
5.2. CALIBRATION STANDARDS 
 
The calibration standards were prepared with phosphate buffer 50 mM, pH 7.4: Acetonitrile 
(ACN) 0.1 % formic acid (50:50, v:v) by dilution of the calibration reference stock solution to 
have eight calibration points: 1000, 400, 200, 100, 50, 10, 5 and 1 nM. 
 
 
5.3. QUALITY CONTROLS 
	  
The Quality Control (QC) solutions were prepared with phosphate buffer 50 mM, pH 7.4: 
ACN 0.1% formic acid (50:50, v:v) by dilution of the QC stock solution to have 1000, 400, 
100, 50, 5 and 1 nM solutions. 
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5.4. VALIDATION PARAMETERS 
	  
5.4.1. SELECTIVITY/SPECIFICITY 
	  
This is the ability of the analytical procedure to assess unequivocally the analyte in the 
presence of components that may be expected to be present. This parameter was assessed 
by injecting a blank sample prepared in the same conditions of the experiment but without 
opicapone 3-O-sulfate. 
The specificity of the assay against opicapone, quercetin, acetaminophen and DCNP was 
evaluated. To blank matrix was added a certain amount of these compounds (100 µM) and 
the samples were treated and analysed to check if there is any interference of these 
compounds at the same retention time of opicapone 3-O-sulfate.  
 
5.4.2. CARRYOVER/CONTAMINATION 
	  
When validating a chromatographic analysis method, tests should be performed to look for 
characteristic peaks occurring at the same retention times as the analytes, or that may 
interfere with subsequent analysis. Contamination or blank response from matrix or reagents 
can affect, also, the accuracy and precision at all concentrations. However low 
concentrations samples are most affected as a percentage of concentrations. 
Carryover was assessed on the chromatographic system by making a single injection of an 
extracted blank matrix after of the last highest concentration of the calibration standard 
(1000 nM). 
 
5.4.3. WORKING AND LINEAR RANGE 
	  
The range of an analytical procedure is the interval between the upper and the lower 
concentration (amounts) of analyte in the sample (including these concentrations) for which 
it has been demonstrated that the analytical procedure has a suitable level of precision and 
accuracy. At the lower end of the concentration range the limiting factors are the values of 
the limits of quantification (LLOQ). At the upper end of the concentration range (ULOQ) 
limitations will be imposed by various effects, depending on the instrument response system. 
FCUP/BIAL 
Opicapone Sulfation: Sulfotransferase Isoforms Characterization	  
41 
	  
The working and linear range was evaluated using three calibration curves obtained from 
three separated runs. The calibration curve consists of eight calibrations standards (1000, 
400, 200, 100, 50, 10, 5 and 1 nM) covering the range including the LLOQ and ULOQ. 
 
5.4.3.1. LLOQ and ULOQ 
	  
The LLOQ and ULOQ of an individual analytical procedure is strictly the lowest or highest 
amounts, respectively, of analyte in a sample that can be quantitatively determined with 
suitable precision and accuracy. The quantification limit is a parameter of quantitative 
assays for low and high levels of compounds in sample matrices, and is used particularly for 
determination of, for example, degradation products. It may also be referred to as the 
sensitivity of a quantitative assay. 
 
5.4.3.2. Calibration Curve 
	  
Within the working range there may exist a linear response range. Within the linear range, 
signal response will have a linear relationship to analyte concentration or property value. 
The extent of this range may be established during the evaluation of the working range. 
 
5.4.4. ACCURACY 
	  
The accuracy of an analytical procedure expresses the closeness of agreement between the 
value, which is accepted either as a conventional true value or an accepted reference value, 
and the determined value.  
Accuracy was measured using five determinations for each of the following concentrations: 
1000, 400, 100, 50, 5 and 1 nM. 
 
5.4.5. PRECISION 
	  
The precision of an analytical procedure expresses the closeness of agreement between a 
series of measurements obtained from multiple sampling of the same homogeneous sample 
under the prescribed conditions. The precision was divided into repeatability and 
intermediate precision assessment. Repeatability expresses the precision under the same 
operating conditions over a short interval of time, during a single analytical run (Intra-batch). 
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The intermediate precision expresses within laboratory variations (Inter-batch) that was 
measured in different days. 
 
5.4.5.1. Repeatability (Intra-batch) 
	  
Repeatability was measured using five determinations for each of the following 
concentrations 1000, 400, 100, 50, 5 and 1 nM, which include LLOQ and ULOQ. 
 
5.4.5.2. Intermediate Precision (Inter-batch) 
	  
Intermediate precision was measured using 90 determinations, from 3 different days, for 
each of the six concentrations, 1000, 400, 100, 50, 5 and 1 nM, that fall within the range 
including LLOQ and ULOQ. 
 
5.4.6. DILUTION INTEGRITY 
	  
Tests whether, in the event that a test sample contains concentrations of analyte falling 
above the validated range of the assay, the sample can be diluted in the appropriate matrix 
into the validated range of the assay, with acceptable accuracy and precision. To assess this 
parameter, a validation specimen was prepared in triplicate with a concentration above the 
ULOQ (10000 nM) and diluted 20-fold in the appropriate matrix into the validated range (1 
nM to 1000 nM). 
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6. LC-MS/MS METHOD 
	  
The analysis of samples extracts for opicapone 3-O-sulfate was performed using a LC-
MS/MS equipment. An Agilent G6460 triple quadrupole mass spectrometer (Agilent 
Technologies, CA, United States) coupled to an Agilent 1200 Infinity HPLC system 
consisting of infinity binary pump G4220A, infinity sampler G4226A, FC/ALS thermostated 
G1330B and infinity column thermostat G1316C was used. The ionization mode was 
electrospray, polarity negative. Electrospray jetstream conditions were as follows: capillary 
voltage, 3500 V; drying gas flow, 10 l/min nitrogen; drying gas temperature, 300 ºC; 
nebulizer pressure, 45 psi; sheath gas temperature, 400 ºC; and sheath gas flow, 11 l/min. 
The mass spectrometer was operated in the multiple reaction monitoring (MRM) mode. The 
MRM transition was m/z 491→394; dwell time, 200 ms; fragmentor voltage, 100 V; and 
collision energy, 25 V.  HPLC separation was achieved on a Zorbax Eclipse XDB-C8 column 
(4.6 x 150 mm; 5 µm; Agilent, USA) using (A) ammonium acetate 25 mM and (B) acetonitrile 
as mobile phases at a flow rate of 0.5 ml/min. Gradient conditions were programmed as 
follows: 20 % B for the first minute, a linear increase to 100 % B to 4 min, remaining at 100 
% B to 8 min, and then reequilibration to 20 % B. A volume of 5 µL was injected and the 
column temperature kept at 40 ºC for the run time of 10 min. 
 
	    
FCUP/BIAL 
Opicapone Sulfation: Sulfotransferase Isoforms Characterization	  
44 
	  
7. CALCULATIONS AND STATISTICS 
 
7.1. CALCULATIONS 
 
Bias 
For analytical samples, accuracy is determined by replicate analysis of samples containing a 
known amount of the analyte. 
Accuracy may be reported using the % of deviation from the expected value Bias (% 
inaccuracy): 
 
% Bias = Mean Concentration Determined – Expected Concentration   x 100 
        Expected Concentration 
 
The mean value should be within 15% of the actual value except at the LLOQ, where it 
should not deviate by more than 20%. 
 
 
Standard Deviation 
The standard deviation, relative standard deviation (% CV) and/or confidence interval should 
be reported for each type of precision investigated. 
 
% CV =     Standard Deviation     x 100 
         Mean Conc. Determined 
 
The precision determined at each concentration level should not exceed 15% of the 
coefficient of variation (CV) except for the LLOQ, where it should not exceed 20% of the CV. 
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7.2. STATISTICAL ANALYSIS 
	  
MS data were acquired and processed (integrated) using the Agilent MassHunter 
Workstation software version B.04.01. Calibration plots of analyte peak area versus 
opicapone 3-O-sulfate nominal concentrations were constructed and a weighted 1/x2 linear 
regression was used. Concentrations of opicapone 3-O-sulfate in validation samples were 
determined from the appropriate calibration curve and used to calculate the bias and 
precision of the method with a Microsoft Excel® worksheet previously validated. 
Analysis of the data and curve-fitting (to obtain Km and Vmax values) was performed using 
nonlinear regression and the algorithms contained in the program GraphPad Prism® 5.02 
(GraphPad Software, Inc.).  
The formation rates of opicapone 3-O-sulfate (nanomole per minute per milligram of protein 
of human intestine S9 fraction) from incubations with a broad substrate concentration range 
were evaluated by fitting the data to the allosteric sigmoidal equation, V = Vmax . S^h/(Kprime + 
S^h), where S is the inhibitor concentration, Vmax is the maximum enzyme velocity, Kprime is 
related to the Km, but is not equal the substrate concentration needed to achieve a half-
maximum enzyme velocity (unless h=1), and h is the Hill slope.  
The formation rates of opicapone 3-O-sulfate (nanomole per minute per milligram of protein 
of human liver S9 fraction) from incubations with a broad substrate concentration range were 
evaluated by fitting the data to the Michaelis-Menten equation, V = Vmax . S/(Km + S), where 
S is the inhibitor concentration, Vmax is the maximum enzyme velocity and Km is the 
Michaelis-Menten constant.  
The formation rates of opicapone 3-O-sulfate (nanomole per minute per milligram of protein 
of SULT1A1*1 or SULT1A1*2) from incubations with a broad substrate concentration range 
were evaluated by fitting the data to the substrate inhibition equation, V = Vmax . S/(Km + 
S*(1+S/Ki)), where S is the inhibitor concentration, Vmax is the maximum enzyme velocity, Km 
is the Michaelis-Menten constant, and Ki is the dissociation constant for substrate binding in 
such a way that two substrates can bind to an enzyme.  
The IC50 was calculated by fitting the percentage of activity versus control: IC50 = 
100/(1+10^((LogIC50-X)*HillSlope))), where X is the inhibitor concentration and the HillSlope 
describes the steepness of the family of curves. 
The one-way ANOVA analysis of variance and Tukey’s multiple comparison tests were used 
to compare the results obtained for liver S9 fraction of the species tested. A value of P<0.05 
was considered to represent a significant difference. 
   
  
 
 
 
 
 
 
 
 
 
CHAPTER III 
 
RESULTS 
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1. BIO-ANALYTICAL METHOD VALIDATION 
	  
1.1. SELECTIVITY/SPECIFICITY 
	  
No co-eluted peaks were observed that could compromise the selectivity of the assay for 
opicapone 3-O-sulfate quantification. A typical chromatogram of extracted blank matrix is 
shown in Figure 5. 
The specificity of the assay against opicapone, quercetin, acetaminophen and DCNP was 
evaluated. To blank matrix was added 100 µM of these compounds and the samples were 
treated and analysed. There is no any interference at the same retention time of opicapone 
3-O-sulfate. 
 
	  
Figure 5  - Representative chromatogram of extracted blank matrix 
 
1.2. CARRYOVER/CONTAMINATION 
	  
A control sample was injected after the injection of the highest calibration sample for 
carryover assessment. This procedure was repeated three times. No peaks were observed 
on control samples, the analytical method is considered to be without contaminations 
between subsequent samples analysed. 
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1.3. WORKING AND LINEAR RANGE 
	  
1.3.1. CALIBRATION CURVE 
	  
The linearity of the assay was assessed using three calibration curves prepared on three 
different days. Calibration curves were obtained by weighted (1/x2) linear regression for the 
peak area of the analyte against the amount of the analyte. The correlation coefficient (r) 
was greater than 0.9965 (Table 2). The % bias for the back-calculated concentrations of the 
calibration specimens which was within 15 % for the entire range, were varying from -8.7 % 
to 11.0 % (Table 1). There was no calibration specimens rejected in the three calibration 
curves. 
 
 
Table 1 - Inter-assay variation for calibration standards of opicapone 3-O-sulfate	  
 Concentration (nM) 
 1 5 10 50 100 200 400 1000 
Run 1 1.02 4.56 9.60 46.00 97.01 196.78 449.52 1105.82 
Run 2 1.01 4.92 9.46 45.45 96.83 197.25 439.03 1099.20 
Run 3 1.01 4.74 9.85 45.46 93.10 197.03 441.77 1124.07 
Mean 1.02 4.74 9.64 45.64 95.65 197.02 443.44 1109.70 
Standard deviation 0.01 0.18 0.20 0.32 2.21 0.24 5.44 12.88 
Precision (%CV) 0.6 3.7 2.0 0.7 2.3 0.1 1.2 1.2 
Bias (%) 1.6 -5.2 -3.6 -8.7 -4.4 -1.5 10.9 11.0 
 
 
 
Table 2 - Calibration curve parameters for opicapone 3-O-sulfate	  
 linear equation: ax + b   Correlation coefficient 
  a  b     
Run 1 530.67 
 
-24.58 
 
0.9965   
Run 2 519.54 
 
-40.36 
 
0.9975   
Run 3 287.61 
 
-84.32 
 
0.9974   
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Typical chromatograms of extracts of low, medium and high calibration standards are shown 
in Figures 6 to 8. 
	  
Figure 6 - Representative chromatogram of 1 nM opicapone 3-O-sulfate in matrix. 
 
	  
Figure 7 - Representative chromatogram of 100 nM opicapone 3-O-sulfate in matrix. 
 
	  
Figure 8 - Representative chromatogram of 1000 nM opicapone 3-O-sulfate in matrix.	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1.3.2. LLOQ AND ULOQ 
	  
The ULOQ and LLOQ is the highest and lowest limits of quantification of the range 
examined, which has acceptable precision and accuracy according to the criteria. 
Accordingly to the results presented in section 1.3.1, the LLOQ is 1 nM and the ULOQ is 
1000 nM. 
 
1.4. ACCURACY 
	  
The accuracy of the method was analysed over the analytical range of 1 to 1000 nM by 
measuring the % bias, which was within 15 % for the entire range, varying from -8.0 % to 
10.2 % (Table 3). 
 
 
Table 3 - Intra-batch precision and accuracy for opicapone 3-O-sulfate 
 Concentration (nM) 
 1 5 50 100 400 1000 
Run 1, n=5 1.07 5.10 47.59 99.23 420.50 1123.96 
 
0.87 4.97 47.36 99.17 407.89 1121.19 
 
0.83 4.50 42.75 93.99 405.18 1085.13 
 
1.15 4.71 50.14 92.07 398.34 1095.17 
 
0.99 4.26 42.15 95.86 417.64 1083.07 
Mean 0.98 4.71 46.00 96.06 409.91 1101.70 
Precision (%CV) 13.8 7.3 7.4 3.3 2.2 1.8 
Bias (%) -1.7 -5.9 -8.0 -3.9 2.5 10.2 
 
1.5. PRECISION 
	  
1.5.1. REPEATABILITY (INTRA-BATCH) 
	  
The repeatability was evaluated using the coefficient of variation and it was analysed over 
the analytical range of 1 to 1000 nM. The coefficient of variation determined in the first intra-
batch at each concentration level (1, 5, 50, 100, 400 and 1000 nM) covering the entire range 
was within 15%, varying from 1.8 % to 13.8 % (Table 3). 
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1.5.2. INTERMEDIATE PRECISION (INTER-BATCH) 
 
The Intermediate precision was evaluated using the coefficient of variation determined in the 
inter-batch. For each concentration level (1, 5, 50, 100, 400 and 1000 nM) covering the 
entire range the coefficient of variation was less than 15 %, varying from 4.1 % to 11.3 % 
(Table 4). 
Table 4 - Inter-batch precision and accuracy for opicapone 3-O-sulfate 
 Concentration (nM) 
 1 5 50 100 400 1000 
       
Run 1, n=5 1.07 4.65 48.87 105.89 466.86 1145.04 
  1.16 4.99 48.76 107.58 453.48 1141.58 
  1.01 4.14 48.26 102.50 467.10 1086.70 
  1.00 4.57 47.21 102.76 405.17 1139.70 
  1.09 4.68 52.51 105.31 513.11 1200.94 
Mean 1.07 4.61 49.12 104.81 461.14 1142.79 
Precision (%CV) 6.1 6.6 4.1 2.1 8.4 3.5 
Bias (%) 6.6 -7.9 -1.8 4.8 15.3 14.3 
	  	  
	   	   	   	   	   	  Run 2, n=5 1.02 4.79 48.13 90.70 386.86 1050.14 
  0.95 4.21 40.89 88.55 422.39 1139.73 
  1.29 4.30 43.02 88.36 371.25 1047.64 
  0.96 4.04 42.72 83.72 361.41 1044.58 
  1.11 4.40 38.39 90.41 395.76 1057.49 
Mean 1.07 4.35 42,63 88.35 387.53 1067.92 
Precision (%CV) 13.2 6.4 8,4 3.2 6.1 3.8 
Bias (%) 6.6 -13.0 -14,7 -11.7 -3.1 6.8 
  
      Run 3, n=5 1.07 5.10 47.59 99.23 420.50 1123.96 
  0.87 4.97 47.36 99.17 407.89 1121.19 
  0.83 4.50 42.75 93.99 405.18 1085.13 
  1.15 4.71 50.14 92.07 398.34 1095.17 
  0.99 4.26 42.15 95.86 417.64 1083.07 
Mean 0.98 4.71 46.00 96.06 409.91 1101.70 
Precision (%CV) 13.8 7.3 7.4 3.3 2.2 1.8 
Bias (%) -1.7 -5.9 -8.0 -3.9 2.5 10.2 
  
      Overall totals, n=15 
      Mean 1.04 4.55 45.92 96.41 419.53 1104.14 
Precision (%CV) 11.3 7.2 8.6 7.7 9.6 4.1 
Bias (%) 3.8 -8.9 -8.2 -3.6 4.9 10.4 
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1.6. DILUTION INTEGRITY 
	  
Five validation specimens were prepared with a concentration above the ULOQ (10000 nM) 
and diluted 20-fold in the appropriate matrix, that brought the analyte concentration within 
the assay range. The determined value for the analyte after dilution was 2.4 %, less than 15 
% established by criteria. 
 
Table 5 - Opicapone 3-O-sulfate dilution integrity	  
Dilution Nominal Found Found Conc x     
factor Concentration Concentration Dilution factor Mean SD CV Bias 
 
nM nM nM nM 
 
% % 
        
  517.38 10347.59     
  511.63 10232.57     
20 10000 489.07 9781.45 10235.11 270.99 2.6 2.4 
  524.85 10497.01     
  515.85 10316.94     
	  
	  
	   	  
FCUP/BIAL 
Opicapone Sulfation: Sulfotransferase Isoforms Characterization	  
53 
	  
2. OPICAPONE SULFATION BY S9 FRACTIONS OF DIFFERENT SPECIES 
	  
Liver, intestine and kidney S9 fractions commercially available from different species were 
used to evaluate their ability to conjugate opicapone to opicapone 3-O-sulfate (Table 6, 
Figure 9).  
 
	  
	  
 
Table 6 - Apparent opicapone 3-O-sulfate rates catalysed by human, rat, dog and monkey S9 
fractions following 60 min incubation. Rates were determined at 10 µM of opicapone. Values 
represent mean ± SEM of 2 determinations. 
 PAPS No PAPS 
S9 fraction Mean ± SEM (fmol.mg prot-1 min-1) 
Human liver* 45.2 ± 0.6 6.5 ± 0.0 
Human intestine 516.0 ± 97.6 8.2 ± 0.7 
Human kidney 21.0 ± 0.5 7.8 ± 0.1 
Monkey liver* 74.5 ± 0.6 5.8 ± 0.6 
Rat liver* 86.2 ± 1.2 5.4 ± 0.1 
Dog liver* 91.8 ± 0.4 7.2 ± 0.9 
 * significantly different according with one-way ANOVA analysis of variance and Tukey’s multiple 
comparison test 
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Figure 9 - Apparent sulfation rates catalysed by human, rat, dog and monkey S9 fraction (0.4 and 
1.0 mg/ml) following 60 min incubation. Rates were determined at 10 µM opicapone. Values 
represent mean ± SEM of duplicates. 
 
 
From the tested S9 fractions, significant higher amounts of opicapone 3-O-sulfate were 
detected in human intestinal S9 fraction in comparison with the other S9 fractions studied. 
Human, rat, monkey and dog liver S9 fractions, produced small amounts of opicapone 
sulfated and human kidney S9 fraction conjugate opicapone at extremely low levels over 
an incubation period of 60 min. Differences were observed in the results obtained for 
opicapone 3-O-sulfation by liver S9 fraction across the species tested.  
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The linearity of opicapone 3-O-sulfation was obtained over 120 min, in all species studied, 
as presented in Table 7 and Figure 10. 
 
 
Table 7 - Apparent sulfation catalysed by human, rat, dog and monkey S9 fractions over 120 min. Rates were determined at 10 
µM of opicapone. Values represent mean ± SEM of duplicates. 
 S9 fraction 
 Human liver Human intestine Monkey liver Rat liver Dog liver 
Time (min) Mean ± SEM (nmol/mg) 
30 1.3 ± 0.0 5.7 ± 0.2 2.1 ± 0.0 2.2 ± 0.2 2.9 ± 0.0 
60 3.0 ± 0.1 31.3 ± 2.0 3.6 ± 0.1 6.2 ± 1.6 5.9 ± 0.5 
120 12.2 ± 1.7 103.2 ± 3.1 6.1 ± 0.1 26.5 ± 0.2 12.8 ± 0.8 
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Figure 10 - Apparent opicapone sulfation catalysed by human, rat, dog and monkey S9 fractions over 120 min. Rates were 
determined at 10 µM opicapone. Values represent mean ± SEM of duplicates. 
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2.1. OPICAPONE SULFATION BY HUMAN S9 FRACTIONS 
	  
Kinetic analysis of opicapone sulfation was performed in human pooled liver and intestine 
S9 fractions. The linearity for the product formation with respect to the protein concentration 
was obtained over the range of 0.1 to 0.4 mg/ml for human intestinal S9 fraction and over 
the range of 0.5 to 2.0 mg/ml for human liver S9 fraction, as presented in Figure 11. As it 
can be observed in Figure 12, the linearity for opicapone 3-O-sulfate formation was obtained 
over 120 min for human intestinal S9 fraction and human liver S9 fraction. 	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Figure 11 - Establishment of linear protein concentration for the in vitro sulfation of 
opicapone by A) human intestinal S9 (0.1, 0.2 and 0.4 mg/ml) and B) human liver 
S9 (0.5, 1.0 and 2.0 mg/ml) incubated for 60 min with opicapone (10 µM). Values 
represent mean ± SEM of duplicates.	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Figure 12 - Establishment of linear time conditions for the in vitro sulfation of 
opicapone by A) human intestinal S9 (0.4 mg/ml) and B) human liver S9 (1.0 
mg/ml) fractions incubated at different time points with opicapone (10 µM). Values 
represent mean ± SEM of duplicates. 
 
 
Each human pooled S9 fraction was incubated with different concentrations of opicapone (1-
100 µM) and the initial rates of sulfation determined. As shown in Figure 13, both 
preparations displayed typical hyperbolic kinetics. The Eadie-Hofstee plots for opicapone 
sulfation in the tested S9 fractions were biphasic, indicating the involvement of more than 
one SULT isoform in opicapone sulfation. The apparent kinetic parameters derived from 
intestinal and liver S9 fraction curve fitted to the allosteric sigmoidal and Michaelis-Menten 
equations, respectively, and kinetic parameters are listed in Table 8. Both apparent Km and 
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Vmax values were higher for liver than for intestine S9 (12 and 7 fold higher, respectively). 
The intrinsic clearance (Clint =Vmax/Km) calculated for intestine was 82.1 µl.mg prot-1 min-1 and 
the one calculated for liver was 44.7 µl.mg prot-1 min-1, about 2-fold lower than the one for 
intestine. 
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Figure 13 - Kinetics of opicapone sulfation in: A) human intestine S9 (0.4 mg/ml) and 
B) human liver S9 (1.0 mg/ml) fractions. Opicapone concentrations ranged 1-100 µM. 
Values represent mean ± SEM of duplicates. The insets show Eadie-Hofstee plots for 
3-O-sulfation of opicapone. 
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Table 8 - Apparent kinetic parameters of opicapone sulfation in human liver and intestine S9 fractions. 
 Km  Vmax   Vmax/ Km 
 µM nmol.mg prot-1 min-1  µl.mg prot-1 min-1 
Human intestinal S9 a 3.90± 2.94 0.32± 0.21 h=0.284± 0.10 µM 82.1 
Human liver S9 b 49.69± 12.27 2.22± 0.25  44.7 
a) rates were fitted to allosteric sigmoidal and b) Michaelis-Menten equation; h) is Hill slope. Values represent best fit values ± 
SEM. 
 
2.2. OPICAPONE SULFATION BY HUMAN RECOMBINANT SULTS 
	  
Seven commercially available SULT enzymes were used to evaluate their ability to 
conjugate opicapone to opicapone 3-O-sulfate (Table 9, Figure 14). From the tested SULTs 
only SULT1A1*1 and 1A1*2 produced significant amounts of opicapone sulfated (1165.9 ± 
127.4 and 1913.2 ± 126.1 fmol.mg prot-1 min-1, respectively). SULT1A2, 1A3, 1E1 and 2A1 
produced small amounts of opicapone 3-O-sulfate (between 28.3-221.1 fmol.mg prot-1 min-
1). No conjugated metabolite formation was detected with SULT1B1 over an incubation 
period of 60 min.  
 
 
Table 9 - Apparent sulfation rates catalysed by human recombinant SULTs following 
60 min incubation. Rates were determined at 10 µM of opicapone. Values represent 
mean ± SEM of duplicates. 
Human Recombinant Mean ± SEM (fmol.mg prot-1 min-1) 
SULT1A1*1 1165.9 ± 127.4 
SULT1A1*2 1913.2 ± 126.1 
SULT1A2 43.8 ± 0.2 
SULT1A3 221.1 ± 3.1 
SULT1B1 4.0 ± 0.1 
SULT1E1 28.3 ± 0.9 
SULT2A1 210.2 ± 1.1 
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Figure 14 - Apparent sulfation rates catalysed by recombinant human SULT (0.4 mg/ml) 
isoforms. Rates were determined at 10 µM opicapone. Values represent mean ± SEM of 
duplicates. 
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2.3. KINETIC OF OPICAPONE SULFATION BY HUMAN RECOMBINANT SULT 
	  
The characterization of opicapone sulfation kinetics was performed for SULT1A1*1 and 
1A1*2. The linearity for the protein concentration was obtained over the range of 10 to 40 
µg/ml, as presented in Figure 15. As it can be observed in Figure 16, the linearity for 
opicapone 3-O-sulfate production was obtained over 240 min for SULT1A1*1 and 1A1*2 
using a protein concentration of 30 µg/ml.  
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Figure 15 - Establishment of linear protein concentration for the in vitro 
sulfation of opicapone. A) Human recombinant SULT1A1*1 (10, 20 and 40 
µg/ml) and B) human recombinant SULT1A1*2 (10, 20 and 40 µg/ml) were 
incubated for 60 min with opicapone (10 µM). Values represent mean ± SEM of 
duplicates. 
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Figure 16 - Establishment of linear time conditions for the in vitro sulfation of 
opicapone. A) Human recombinant SULT1A1*1 (30 µg/ml) and B) human 
recombinant SULT1A1*2 (30 µg/ml) were incubated at different time points with 
opicapone (10 µM). Values represent mean ± SEM of duplicates. 
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Each recombinant enzyme was incubated with different concentrations of opicapone (1-100 
µM) and the initial rates determined. Accordingly, the experimental data from SULT1A1*1 
and 1A1*2 was fitted with a substrate inhibition profile. The resulting curves are represented 
in Figure 17 and the apparent kinetic parameters Km and Vmax derived from these curves, are 
shown in Table 10. SULT1A1*1 and 1A1*2 had similar affinities for the conjugation of 
opicapone as shown by the apparent Km values determined. SULT1A1*1 and 1A1*2 had 
apparent affinities close to 20 µM.   
0 20 40 60 80 100
0.0
0.5
1.0
1.5
Concentration (µM)
O
pi
ca
po
ne
 3
-O
-s
ul
fa
te
(n
m
ol
.m
g 
pr
ot
-1
m
in
-1
)
0 20 40 60 80 100
0.0
0.5
1.0
1.5
2.0
2.5
Concentration (µM)
O
pi
ca
po
ne
 3
-O
-s
ul
fa
te
(n
m
ol
.m
g 
pr
ot
-1
m
in
-1
)
A)
B)
	  
Figure 17 - Kinetics of opicapone sulfation by recombinant human SULT (30 µg/ml) 
isoforms: A) SULT1A1*1 and B) SULT1A1*2. Opicapone concentrations ranged 1-100 µM. 
Values represent mean ± SEM of duplicates. Lines represent the fitting curves to substrate 
inhibition equation. 
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Table 10 - Apparent kinetic parameters of opicapone sulfation in human recombinant SULT enzymes. 
 Km  Vmax   Vmax / Km 
 µM nmol mg prot-1 min-1  µl.mg prot-1 min-1 
SULT1A1*1c 16.62± 8.89 2.41± 0.82 Ki=39.37±21.33 145.0 
SULT1A1*2c 26.71± 21.55 5.46± 3.19 Ki =27.50±22.48 204.4 
c) Substrate inhibition; Ki is the substrate inhibition constant. Values represent best fit values ± SEM. 
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2.4. INHIBITION OF OPICAPONE SULFATION BY TYPICAL SUBSTRATES FOR 
SULT ISOFORMS 
	  
To further evaluate the potential interaction of typical substrates for SULT isoforms in 
opicapone sulfation, selective inhibitors as acetaminophen (substrate for SULT), quercetin 
(substrate for SULT1A1) and DCNP (substrate for SULT) were tested. 
No inhibition was observed on opicapone sulfation in the presence of acetaminophen (1, 5, 
10, 50, 100, 200, 400 and 500 µM), in liver pooled S9 fraction as presented in Figure 18. 
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Figure 18 - Inhibitory effect of acetaminophen on opicapone sulfation. Opicapone 
sulfation was evaluated in pooled liver S9 fraction (1.0 mg/ml) at the concentration of 
100 µM opicapone in the presence of inhibitor (1, 5, 10, 50, 100, 200, 400 and 500 
µM). Values represent mean ± SEM of duplicates.  
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The effect of quercetin and DCNP (0.05, 0.1, 0.5, 1, 5, 10, 50, 100 µM) on opicapone (100 
µM) sulfation activities in human pooled S9 fractions was also investigated. 
As shown in Figure 19 and Table 11, quercetin and DCNP completely inhibited opicapone 
sulfation with an IC50 of 1795 nM and 383.3 nM in human liver S9 fraction, and an IC50 of 
1483 nM and 181 nM for human intestinal S9 fraction, respectively.  
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Figure 19 - Inhibitory effect of quercetin and DCNP on opicapone sulfation. 
Opicapone sulfation was evaluated in: A) pooled intestinal S9 fraction (0.4 mg/ml); 
B) pooled liver S9 fraction (1.0 mg/ml), at the concentration of 100 µM opicapone in 
the presence of inhibitors at the concentrations of 0.05, 0.1, 0.5, 1, 5, 10, 50, 100 
µM. Values represent mean ± SEM of duplicates.  
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Table 11 - Inhibition of opicapone 3-O-sulfate by DCNP and quercetin in the presence of human S9 fractions. IC50 (nM) values 
for DCNP and quercetin at the concentration of 100 µM opicapone. Values presented as a parameter estimate with 95% 
Confidence Intervals. 
 
IC50 DCNP IC50 Quercetin 
 nM 
 
nM 
Human liver S9 fraction 383.3 (360.6 to 407.2) 1795.0 (1494.0 to 2156.0) 
Human intestine S9 fraction 181.0 (157.4 to 208.2) 1483.0 (1350.0 to 1629.0) 
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An IC50 of 529 nM and 245 nM were obtained for SULT1A1*1 for quercetin and DCNP, 
respectively, and an IC50 of 232 nM and 700 nM for SULT1A1*2, for quercetin and DCNP, 
respectively (Figure 20, Table 12). The human S9 fraction IC50 values for DCNP and 
quercetin are closest to IC50 of SULT1A1*1 suggesting that SULT1A1*1 (the highest 
frequent allele) may plays a predominant role in opicapone 3-O-sulfation. 
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Figure 20 - Inhibitory effect of quercetin and DCNP on opicapone sulfation. 
Opicapone sulfation was evaluated in: A) SULT1A1*1 and B) SULT1A1*2 with 30.0 
µg/ml of protein concentration, at the concentration of 100 µM opicapone in the 
presence of inhibitors (0.05, 0.1, 0.5, 1, 5, 10, 50, 100 µM). Values represent mean 
± SEM of duplicates.  
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Table 12 - Inhibition of opicapone sulfate by DCNP and quercetin in the presence of human recombinant SULTs. IC50 (nM) 
values for DCNP and quercetin at the concentration of 100 µM opicapone. Values presented as a parameter estimate with 95% 
Confidence Intervals	  
 
IC50 DCNP IC50 Quercetin 
 nM 
 
nM 
Human Rec SULT1A1*1 245.0 (186.4 to 321.8) 529.0 (162.7 to 1721.0) 
Human Rec SULT1A1*2 700.0 (553.6 to 886.3) 232.0 (150.2 to 359.4) 
 
 
  
  
 
 
 
 
 
 
 
 
 
CHAPTER IV 
 
DISCUSSION AND CONCLUSION 
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Opicapone, is a novel third generation COMT inhibitor currently under phase III clinical trials 
for use as adjunctive therapy in levodopa-treated PD patients. In humans, opicapone is 
mainly conjugated by sulfotransferases giving opicapone 3-O-sulfate, a major opicapone 
inactive metabolite present in human plasma. Other minor metabolites that compete with the 
sulfated metabolite in the opicapone metabolism are: 3-O-methyl, 3-O-glucuronide and the 
amine N-oxide reduced metabolite (Rocha et al. 2013). 
The purpose of this work was to characterize the kinetics for the conversion of opicapone 
into sulfated metabolite by intestinal, kidney and liver S9 fractions and by human 
recombinant SULTs. 
In this study, a sensitive and selective method for the quantification of opicapone 3-O-sulfate 
based on LC–MS/MS technology was established. The assay demonstrated excellent 
accuracy, precision, linearity and specificity for the intended purpose in accordance with 
FDA regulations for the validation of bioanalytical methods. Linearity was proven over the 
range of 1 to 1000 nM. The intra- and inter-day coefficient of variation was less than 13.8 % 
and the accuracy was between -8.0 % and 10.2 %. The lower limit of quantification (LLOQ) 
was 1 nM and the method was precise and accurate for 20-fold dilution of samples. 
Validation data shows that method is selective, sensitive and robust.  
To better characterize the extent of the formation of opicapone sulfated, S9 fractions of 
different species were initially used. S9 fraction was used because it is a routine model 
system used in phase II metabolic studies involving sulfation of drugs and other xenobiotics 
(Tang et al. 2012). 
Results indicate that all tested S9 fractions sulfated opicapone. Human intestinal S9 fraction 
(516.0 ± 97.6 fmol.mg prot-1 min-1) has the highest sulfating capacity. Human, rat, monkey 
and dog liver S9 fractions and human kidney S9 fraction produced small amounts (ranged 
21.0 - 91.8 fmol.mg prot-1 min-) of the sulfated metabolite. The values obtained for liver S9 
fraction of the species tested were significantly different according applying one-way ANOVA 
analysis of variance and Tukey’s multiple comparison test for 95% significance. However, no 
conclusion can be taking not only because of the differential expression of SULTs in the 
various tissues, but also because it is not possible to quantify the levels of the individual 
enzymes in the tissues preparations.  
Human liver and intestinal S9 fractions displayed typical hyperbolic kinetics (Figure 13). The 
kinetic analysis indicates that more than one enzyme appeared to participate in the 
formation of opicapone metabolite in S9 fractions. Eadie-Hofstee plots for opicapone 
sulfation reactions were biphasic for the tested human S9 fractions, suggestive of 
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involvement of at least two components, one with a high affinity and low capacity, and 
another with a low affinity and high capacity. 
 The apparent kinetic parameters Km and Vmax values were higher for human liver than for 
human intestine S9 fraction. The intrinsic clearance (CIint) values of human liver and intestine 
S9 fractions for the formation of opicapone 3-O-sulfate were 44.7 and 82.1 µl.mg prot-1 min-1, 
respectively, suggesting that the formation of opicapone sulfated in human intestine was 
efficient. The CIint value of human intestine S9 fraction was 2-fold higher than of human liver 
S9 fraction, that suggest the presence of SULT isoforms in intestine that contribute for 
opicapone metabolism and elimination. 
Among seven human recombinant SULTs tested, several enzymes (SULT1A1, 1A2, 1A3, 
1E1 and 2A1) were capable of conjugating opicapone albeit at different levels. In this study, 
we identified SULT1A1 (SULT1A1*1 and SULT1A1*2) isoform as the major SULT involved 
in 3-O-sulfation of opicapone with a Km values of 16.62 ± 8.89 and 26.71 ± 21.55 µM, for the 
alleles SULT1A1*1 and SULT1A1*2, respectively. SULT1A1 is generally recognized as the 
major xenobiotic-metabolizing SULT, as a result of its capacity to accept a very wide range 
of substrates, and this enzyme accounted for more than 50 % of total SULT protein in the 
liver. SULT2A1 a major isoform in the liver, second in abundance to SULT1A1, contribute to 
opicapone sulfation in lower extent as well as SULT1A3 an extrahepatic enzyme involved to 
selectively sulfate catecholamines (Riches et al. 2009). 
Opicapone sulfation by SULT1A1 showed deviation from the typical Michaelis-Menten 
kinetics resulting in a concentration-dependent self-inhibition. The affinity of opicapone 3-O-
sulfate by human recombinant SULT1A1 is 2 to 3-fold higher than the human liver S9 
fraction, suggesting that SULT1A1 may be the primary isoform involved in opicapone 
sulfation in liver. However, the involvement of other isoforms at higher substrate 
concentrations should be considered. In the small intestine, the kinetic analysis of opicapone 
sulfation revealed an affinity for the conjugation 12-fold higher for intestinal S9 fraction than 
for liver S9 fraction, with a Km of 3.90 ± 2.94 and 49.69 ± 12.27 µM, respectively. The 
observed highest affinity of opicapone sulfation may indicate that intestinal opicapone 
sulfation may be performed by other isoform. Additionally SULT1A1, was much less 
prevalent in small intestine and it was present at less than half the level of the liver 
(representing less than 20 % of total SULT protein) (Riches et al. 2009). The opicapone 
sulfation clearance (CIint) was significantly lower for the human intestine and liver S9 fraction 
than for SULT1A1 isoforms, suggesting that although the first-pass sulfation of opicapone in 
intestine may represent a significant contribution to the opicapone metabolism, liver sulfation 
may represent the major contributor due to the high prevalence of SULT1A1 in liver tissues. 
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In the present study, quercetin and DCNP selectively inhibit opicapone sulfation in liver and 
intestinal S9 fractions, with IC50 values of 383.3 nM and 1795 nM for liver S9 fraction and 
181.0 nM and 1483.0 nM for intestine S9 fraction (Figure 19). In contrast, acetaminophen 
that is a known substrate for SULT1A1 and SULT1A3 (Reiter et al. 1982; Pacifici 2004) had 
no significant effect on the formation of opicapone 3-O-sulfate in human liver S9 fraction 
incubated with 100 µM of opicapone. The result obtained may indicate that the opicapone 
sulfation and acetaminophen sulfation may be performed by different isoforms, or the 
concentrations of acetaminophen used were not sufficient to inhibit the formation of 
opicapone 3-O-sulfate. 
The comparison of the apparent Km values obtained for the human recombinant enzymes 
evaluated with those for human S9 fractions, did not clarify which enzymes were involved in 
S9 fraction sulfation and clearly indicate that more than one SULT are involved in opicapone 
sulfation. Among the hepatic SULTs, SULT1A1 had the highest formation rate of opicapone 
3-O-sulfate, however, the Km was significantly lower than the Km obtained for human liver S9 
fraction, which may indicate that higher affinity SULTs may contribute to the opicapone 
sulfation. Furthermore, the high affinity of opicapone sulfation by the intestinal S9 fraction 
may suggest that other SULT isoform than SULT1A1 may be involved in opicapone 
sulfation. Besides the enzymes involved, sulfation will be dependent not only on the kinetics 
of the reaction but also on the amount of compound that reaches the respective tissue and 
most significantly on the enzyme levels present in the tissues. Clinical studies with 
opicapone showed that the maximal plasma concentration with the therapeutic dose of 50 
mg is 522 ng/ml (1.29 µM), which is much less than the Km obtained for S9 fraction. Given 
the high catalytic efficiency and expression levels of SULTs in intestinal tissue, it can be 
concluded that the first-pass metabolism within the intestinal cells contributes significantly to 
the formation of opicapone 3-O-sulfate, the major opicapone metabolite found in vivo, in 
human and rat plasma. 
In conclusion, sulfation is an important metabolic pathway of opicapone and multiple SULTs 
are capable of catalyzing sulfation of opicapone. The results obtained in the present study 
further support the role of intestine in opicapone sulfation and strongly suggest that 
opicapone 3-O-sulfation is mainly catalyzed by SULT1A1 isoforms in humans. 
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